0.41Open0.38Pre Close626 Volume1.36K Open Interest4.00Strike Price28.63KTurnover227.78%IV10.55%PremiumDec 20, 2024Expiry Date0.17Intrinsic Value100Multiplier7DDays to Expiry0.44Extrinsic Value100Contract SizeAmericanOptions Type0.6149Delta0.2923Gamma6.95Leverage Ratio-0.0378Theta0.0004Rho4.27Eff Leverage0.0022Vega
Trevi Therapeutics Stock Discussion
📊⚡️📊
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Thursday, 12th December at 7:30 am
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160
The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 20...
Trevi Therapeutics Announces Positive Outcome From SAMPLE Size Re-Estimation Resulting in No Change to the Current SAMPLE Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
No comment yet